Company news

Trevi Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences

January 4, 2023

Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference

December 18, 2022

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

November 13, 2022

Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference

November 7, 2022

Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022

November 2, 2022

Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting

October 26, 2022

Correction: Trevi Therapeutics, Inc.

September 22, 2022

Trevi Therapeutics Announces Proposed Public Offering

September 21, 2022

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

September 18, 2022

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022

August 29, 2022

Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release

August 23, 2022

Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

August 10, 2022

Trevi Therapeutics to Present at Upcoming August Conferences

August 8, 2022

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

August 3, 2022

Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS)

July 6, 2022

Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis

June 28, 2022

Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention

June 6, 2022

Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update

May 11, 2022

Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022

May 4, 2022

Trevi Therapeutics to Present at Upcoming May Meetings

May 2, 2022

Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

April 10, 2022

Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market

April 6, 2022

Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

March 21, 2022

Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update

March 16, 2022

Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough

March 14, 2022

Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022

March 8, 2022

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

February 23, 2022

Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

January 31, 2022

Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications

January 4, 2022

Trevi Therapeutics to Attend Multiple Conferences in January 2022

December 15, 2021

Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases

November 14, 2021

Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update

November 9, 2021

Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

November 8, 2021

Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021

November 2, 2021

Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)

October 12, 2021

Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference

October 6, 2021

Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market

September 29, 2021

Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update

August 11, 2021

Trevi Therapeutics Announces Additions to the Senior Leadership Team

August 8, 2021

Trevi Therapeutics to Report Q2 2021 Financial Results on August 12

August 4, 2021

Trevi Therapeutics to Present at 2021 BIO Digital Conference

June 8, 2021

Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update

May 12, 2021

Trevi Therapeutics to Report Q1 2021 Financial Results on May 13

May 5, 2021

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

April 6, 2021

Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates

March 24, 2021

Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25

March 17, 2021

Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference

February 17, 2021

Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer

January 31, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.